Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies HINGHAM, Mass. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first
Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union HINGHAM, Mass. , July 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first
Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology HINGHAM, Mass. , July 11, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first
The study was conducted over two days by a team of global key opinion leaders and with participation of executives from the medical industry HINGHAM, Mass. , June 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first
Microbot Medical Closes Fourth Registered Direct Offering Priced At-The-Market under Nasdaq Rules HINGHAM, Mass. , June 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it closed its previously announced registered direct offering for the purchase and sale of
HINGHAM, Mass. , June 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 624,618 shares of the Company’s common stock at a purchase price of $3.25 per share of common stock in a registered
Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive HINGHAM, Mass. , June 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic Surgical System, the first single-use endovascular robotic
Company Believes the Continuous Accumulation of Peer-Reviewed Data will Accelerate the Adoption of its Novel Interventional Endovascular System Once Commercialized HINGHAM, Mass. , June 16, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is encouraged by the continued participation
HINGHAM, Mass. , June 06, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common
